463 related articles for article (PubMed ID: 19414635)
1. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
Thurberg BL; Fallon JT; Mitchell R; Aretz T; Gordon RE; O'Callaghan MW
Circulation; 2009 May; 119(19):2561-7. PubMed ID: 19414635
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of recombinant alpha-galactosidase A therapy for amelioration of the cardiovascular manifestations of Fabry disease: an important role for endomyocardial biopsy.
Buja LM
Circulation; 2009 May; 119(19):2539-41. PubMed ID: 19451361
[No Abstract] [Full Text] [Related]
3. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
4. Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies.
Thurberg BL; Randolph Byers H; Granter SR; Phelps RG; Gordon RE; O'Callaghan M
J Invest Dermatol; 2004 Apr; 122(4):900-8. PubMed ID: 15102080
[TBL] [Abstract][Full Text] [Related]
5. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
Thurberg BL; Rennke H; Colvin RB; Dikman S; Gordon RE; Collins AB; Desnick RJ; O'Callaghan M
Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
Eng CM; Guffon N; Wilcox WR; Germain DP; Lee P; Waldek S; Caplan L; Linthorst GE; Desnick RJ;
N Engl J Med; 2001 Jul; 345(1):9-16. PubMed ID: 11439963
[TBL] [Abstract][Full Text] [Related]
7. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
Germain DP; Waldek S; Banikazemi M; Bushinsky DA; Charrow J; Desnick RJ; Lee P; Loew T; Vedder AC; Abichandani R; Wilcox WR; Guffon N
J Am Soc Nephrol; 2007 May; 18(5):1547-57. PubMed ID: 17409312
[TBL] [Abstract][Full Text] [Related]
8. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
Desnick RJ; Banikazemi M
Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
[TBL] [Abstract][Full Text] [Related]
9. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.
Wilcox WR; Banikazemi M; Guffon N; Waldek S; Lee P; Linthorst GE; Desnick RJ; Germain DP;
Am J Hum Genet; 2004 Jul; 75(1):65-74. PubMed ID: 15154115
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry.
Kitagawa T; Ishige N; Suzuki K; Owada M; Ohashi T; Kobayashi M; Eto Y; Tanaka A; Mills K; Winchester B; Keutzer J
Mol Genet Metab; 2005 Jul; 85(3):196-202. PubMed ID: 15979031
[TBL] [Abstract][Full Text] [Related]
12. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
13. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
[TBL] [Abstract][Full Text] [Related]
14. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease.
Itier JM; Ret G; Viale S; Sweet L; Bangari D; Caron A; Le-Gall F; Bénichou B; Leonard J; Deleuze JF; Orsini C
J Inherit Metab Dis; 2014 Nov; 37(6):1013-22. PubMed ID: 24850378
[TBL] [Abstract][Full Text] [Related]
15. Fabry disease: treatment and diagnosis.
Rozenfeld PA
IUBMB Life; 2009 Nov; 61(11):1043-50. PubMed ID: 19859978
[TBL] [Abstract][Full Text] [Related]
16. Immunoelectron-microscopic detection of globotriaosylceramide accumulated in the skin of patients with Fabry disease.
Kanekura T; Fukushige T; Kanda A; Tsuyama S; Murata F; Sakuraba H; Kanzaki T
Br J Dermatol; 2005 Sep; 153(3):544-8. PubMed ID: 16120140
[TBL] [Abstract][Full Text] [Related]
17. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
Ortiz A; Oliveira JP; Wanner C; Brenner BM; Waldek S; Warnock DG
Nat Clin Pract Nephrol; 2008 Jun; 4(6):327-36. PubMed ID: 18431378
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
[TBL] [Abstract][Full Text] [Related]
19. Pediatric Fabry disease.
Ries M; Gupta S; Moore DF; Sachdev V; Quirk JM; Murray GJ; Rosing DR; Robinson C; Schaefer E; Gal A; Dambrosia JM; Garman SC; Brady RO; Schiffmann R
Pediatrics; 2005 Mar; 115(3):e344-55. PubMed ID: 15713906
[TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.
Schiffmann R; Floeter MK; Dambrosia JM; Gupta S; Moore DF; Sharabi Y; Khurana RK; Brady RO
Muscle Nerve; 2003 Dec; 28(6):703-10. PubMed ID: 14639584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]